How Much Does Wegovy Cost in Tennessee in 2026?

Wegovy Retail Price at Tennessee Pharmacies

The Novo Nordisk wholesale acquisition cost for Wegovy is $1,349 per month, and Tennessee retail pharmacies (CVS, Walgreens, Kroger, independent pharmacies across Nashville, Memphis, Knoxville, and Chattanooga) generally match or slightly exceed that figure for cash-pay patients [1]. This price applies to the maintenance dose of semaglutide 2.4 mg administered once weekly by subcutaneous injection.

Prices can vary by $50 to $100 depending on the pharmacy. GoodRx and similar discount aggregators occasionally show Tennessee cash prices between $1,280 and $1,370, but these fluctuate week to week. Without insurance or a manufacturer coupon, a full year of Wegovy therapy costs roughly $16,188 out of pocket. That figure makes cost-reduction strategies essential for most Tennessee patients. The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo, confirming the clinical value behind that price tag [2].

Cash-pay patients should ask their pharmacist about 90-day fills, which some Tennessee pharmacies offer at a per-unit discount. Comparing prices at independent pharmacies in smaller Tennessee markets (Clarksville, Jackson, Murfreesboro) may also yield modest savings over chain locations in Nashville or Memphis.

Tennessee Insurance Coverage for Wegovy

Commercial insurance coverage for Wegovy in Tennessee has expanded significantly since the drug's FDA approval in June 2021 [1]. BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, and Aetna plans sold in the state now include Wegovy on their formularies, though nearly all require prior authorization and step therapy documentation.

To obtain prior authorization in Tennessee, prescribers typically must document a BMI of 30 or higher (or 27 or higher with a weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia), a failed trial of lifestyle modification lasting at least 6 months, and a face-to-face or telehealth evaluation. Some plans also require documentation that the patient has tried phentermine or another older weight-loss medication first.

Copays for commercially insured Tennessee patients who clear prior authorization range from $25 to $150 per month, depending on the plan tier. High-deductible plans may require full cash price until the deductible is met. Employer-sponsored plans vary widely. Tennessee state employee health plans through the State Group Insurance Program have historically excluded anti-obesity medications, though coverage policies are reviewed annually.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has stated: "The biggest barrier to GLP-1 therapy isn't the prescription. It's the insurance denial letter that follows it." Tennessee patients facing denials should request a peer-to-peer review, which succeeds in an estimated 30% to 40% of appealed cases [3].

TennCare and Tennessee Medicaid: No Coverage for Weight Management

TennCare, Tennessee's Medicaid managed care program, does not cover Wegovy for chronic weight management as of May 2026. TennCare formularies include semaglutide only under the Ozempic brand name for type 2 diabetes at doses up to 2 mg, not the 2.4 mg Wegovy formulation indicated for obesity.

This gap affects roughly 1.7 million TennCare enrollees statewide. The Treat and Reduce Obesity Act, which would mandate Medicare and Medicaid coverage of FDA-approved anti-obesity medications, has been introduced repeatedly in Congress but has not passed as of 2026 [4]. Tennessee lawmakers have not enacted state-level legislation requiring TennCare to cover GLP-1 receptor agonists for weight loss.

TennCare enrollees with a concurrent type 2 diabetes diagnosis may qualify for Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg) through TennCare's diabetes formulary. While Ozempic is not FDA-approved for weight management, some patients experience weight loss as a secondary benefit. Prescribers should document glycemic control as the primary indication [5].

For TennCare patients who do not have diabetes, compounded semaglutide or patient assistance programs remain the primary alternatives. Novo Nordisk's patient assistance program provides brand-name Wegovy at no cost to qualifying uninsured or underinsured patients with household incomes below 400% of the federal poverty level.

Compounded Semaglutide 2.4 mg in Tennessee: Legality and Pricing

Compounded semaglutide 2.4 mg is available in Tennessee through licensed 503A compounding pharmacies at an average cost of approximately $199 per month. This represents an 85% savings compared to brand-name Wegovy.

Tennessee follows federal compounding law under the Drug Quality and Security Act (DQCA) of 2013. Licensed 503A pharmacies in Tennessee may compound semaglutide based on a valid patient-specific prescription when a prescriber determines that a commercially available product is not appropriate for that individual patient (for example, due to cost-related nonadherence, allergy to an inactive ingredient, or need for a non-standard dose) [6].

The FDA placed semaglutide on its drug shortage list from 2022 through early 2025, which expanded 503A compounding access. As of 2026, Novo Nordisk has largely resolved supply constraints for Wegovy, and the FDA removed semaglutide from the shortage list in February 2025. However, 503A pharmacies in Tennessee may still compound semaglutide when the prescriber documents a clinical reason for a patient-specific compounded preparation.

Key considerations for Tennessee patients choosing compounded semaglutide:

• Verify the pharmacy holds an active Tennessee Board of Pharmacy license
• Confirm the pharmacy compounds under 503A (patient-specific) or 503B (outsourcing facility) federal guidelines
• Ask for a certificate of analysis showing potency, sterility, and endotoxin testing
• Compounded semaglutide is not FDA-approved and is not interchangeable with Wegovy

The American Association of Clinical Endocrinology (AACE) has noted in its 2023 obesity treatment guidelines: "Compounded GLP-1 receptor agonists should only be obtained from pharmacies that comply with USP 797 sterile compounding standards and state board of pharmacy regulations" [7].

The Novo Nordisk Savings Card: How It Works in Tennessee

The Novo Nordisk WeGoTogether savings card is the single most effective cost-reduction tool for commercially insured Tennessee patients. Eligible patients pay as little as $0 per 28-day fill, with Novo Nordisk covering up to $500 in out-of-pocket costs per fill.

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, TRICARE, or any federal or state government program), a valid Wegovy prescription, and U.S. residency. Tennessee patients can enroll online or through their prescriber's office. The card activates at the pharmacy and applies automatically at the point of sale [1].

Limitations exist. The savings card covers a maximum of 13 fills per calendar year. Patients on high-deductible plans may find that the $500-per-fill cap does not fully cover their out-of-pocket cost during the deductible phase, leaving a remaining balance of $800 or more per fill. Once the annual deductible is met, the savings card typically reduces the copay to $0.

Patients whose commercial plans explicitly exclude anti-obesity medications do not qualify for the savings card, since there is no underlying insurance claim for the card to supplement. These patients should explore the Novo Nordisk Patient Assistance Program (PAP) or compounded semaglutide as alternatives.

Telehealth Prescribing of Wegovy in Tennessee

Tennessee law permits prescribing Wegovy via telehealth, and multiple telehealth platforms serve the state. The Tennessee Board of Medical Examiners requires that a telehealth prescriber establish a valid provider-patient relationship, which can occur through a synchronous audio-video visit [8].

The Ryan Haight Act governs controlled substance prescribing via telehealth at the federal level, but semaglutide is not a controlled substance, so these restrictions do not apply to Wegovy prescriptions. Tennessee telehealth prescribers can write Wegovy prescriptions after a virtual evaluation without an in-person visit.

HealthRX and similar telehealth platforms offer Wegovy consultations to Tennessee residents with typical consultation fees ranging from $49 to $149 per visit. Some platforms bundle the consultation fee into a monthly subscription that includes the medication, lab monitoring, and ongoing provider access. For patients in rural Tennessee counties where endocrinologists and obesity medicine specialists are scarce, telehealth removes a significant geographic barrier.

Tennessee pharmacies accept electronic prescriptions from telehealth providers licensed in the state. Patients can fill their Wegovy prescription at any Tennessee pharmacy or use a mail-order pharmacy. The Novo Nordisk savings card works regardless of whether the prescription originated from an in-person or telehealth visit.

Comparing Wegovy to Other GLP-1 Options in Tennessee

Wegovy is not the only GLP-1 receptor agonist available to Tennessee patients. Understanding the alternatives helps patients and prescribers make informed cost-benefit decisions.

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg): Same active ingredient as Wegovy but FDA-approved for type 2 diabetes, not weight management. Tennessee retail price is approximately $935 per month. Insurance coverage is broader because diabetes medications face fewer formulary restrictions. Off-label prescribing for weight loss is common but may not be covered by insurance [5].

Zepbound (tirzepatide 2.5 mg to 15 mg): A dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. FDA-approved for chronic weight management in November 2023. The SURMOUNT-1 trial (N=2,539) showed 20.9% mean weight loss at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo [9]. Tennessee retail price is approximately $1,059 per month. Some Tennessee insurers cover Zepbound with prior authorization, and Eli Lilly offers a savings card program.

Saxenda (liraglutide 3 mg): An older GLP-1 receptor agonist requiring daily injection. Mean weight loss in clinical trials was approximately 8% at 56 weeks [10]. Tennessee retail price is approximately $1,349 per month. Less commonly prescribed since Wegovy's approval due to the superior efficacy and convenience of once-weekly dosing.

For Tennessee patients whose primary goal is cost minimization, compounded semaglutide at $199 per month or compounded tirzepatide (where available from licensed 503A pharmacies) may offer the most accessible entry point into GLP-1 therapy.

Tips to Reduce Wegovy Costs in Tennessee

Tennessee patients can stack several strategies to minimize out-of-pocket Wegovy expenses.

First, apply for the Novo Nordisk savings card before filling the first prescription. This step alone can eliminate copays for commercially insured patients. Second, compare prices across at least three pharmacies. Use GoodRx, RxSaver, or call pharmacies directly. Prices at Tennessee Kroger and Costco pharmacies (Costco does not require membership for pharmacy purchases) sometimes run below chain competitors.

Third, ask your prescriber about prior authorization paperwork early. Delayed PA submissions can result in weeks without medication. Many Tennessee obesity medicine clinics have staff dedicated to PA processing who can submit within 24 hours of the prescription.

Fourth, explore manufacturer patient assistance if you are uninsured or underinsured. Novo Nordisk's PAP provides free Wegovy to qualifying patients. Income documentation is required. Approval typically takes 2 to 4 weeks.

Fifth, consider compounded semaglutide as a bridge. Some Tennessee patients use compounded semaglutide during the Wegovy dose-escalation phase (months 1 through 4, at doses of 0.25 mg to 1.7 mg) and switch to brand-name Wegovy at the 2.4 mg maintenance dose once insurance coverage is confirmed. This approach can save $4,000 or more during the titration period.

The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity recommends that "cost and insurance coverage should be discussed at the time of prescribing, and clinicians should assist patients in identifying the most affordable access pathway" [11].

What to Expect During Wegovy Treatment

Wegovy follows a 16-week dose-escalation schedule: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1 mg, and 1.7 mg (each for 4 weeks), reaching the 2.4 mg maintenance dose at week 17. This gradual titration reduces gastrointestinal side effects, which are the most common reason for early discontinuation [2].

In STEP-1, the most frequently reported adverse events with semaglutide 2.4 mg were nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (24.2%). Most GI symptoms were mild to moderate and decreased after the first 8 to 12 weeks of treatment [2]. Tennessee prescribers typically recommend eating smaller meals, avoiding high-fat foods, and staying hydrated during the titration phase.

Weight loss with Wegovy is dose-dependent and progressive. In STEP-1, participants lost an average of 6% of body weight by week 12 and 14.9% by week 68 [2]. The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease, with a hazard ratio of 0.80 (95% CI, 0.72 to 0.90; P<0.001) [12].

Tennessee patients should expect monthly or quarterly follow-up visits (in person or via telehealth) to monitor weight, blood pressure, heart rate, and potential side effects. Baseline and periodic labs including hemoglobin A1c, lipid panel, liver function, and kidney function are standard practice.